Tisdag 3 Februari | 04:10:15 Europe / Stockholm

Prenumeration

Kalender

Est. tid*
2026-01-12 - Extra Bolagsstämma 2026
2025-08-28 - Kvartalsrapport 2025-Q2
2025-06-06 - X-dag ordinarie utdelning CRNA 0.00 NOK
2025-06-05 - Årsstämma
2025-04-10 - Bokslutskommuniké 2024
2024-08-29 - Kvartalsrapport 2024-Q2
2024-06-19 - Årsstämma
2024-06-06 - X-dag ordinarie utdelning CRNA 0.00 NOK
2024-04-25 - Bokslutskommuniké 2023
2023-10-04 - Split CRNA 30:1
2023-08-24 - Kvartalsrapport 2023-Q2
2023-05-22 - Årsstämma
2023-04-21 - X-dag ordinarie utdelning CRNA 0.00 NOK
2023-03-09 - Extra Bolagsstämma 2023
2023-02-16 - Bokslutskommuniké 2022
2022-11-03 - Kvartalsrapport 2022-Q3
2022-08-18 - Kvartalsrapport 2022-Q2
2022-05-12 - Kvartalsrapport 2022-Q1
2022-04-20 - Årsstämma
2022-04-07 - X-dag ordinarie utdelning CRNA 0.00 NOK
2022-02-17 - Bokslutskommuniké 2021
2021-11-25 - Extra Bolagsstämma 2021
2021-11-04 - Kvartalsrapport 2021-Q3
2021-08-18 - Kvartalsrapport 2021-Q2
2021-05-06 - Kvartalsrapport 2021-Q1
2021-03-18 - X-dag ordinarie utdelning CRNA 0.00 NOK
2021-03-17 - Årsstämma
2021-02-18 - Bokslutskommuniké 2020
2020-11-05 - Kvartalsrapport 2020-Q3
2020-08-20 - Kvartalsrapport 2020-Q2
2020-05-07 - Kvartalsrapport 2020-Q1
2020-04-30 - X-dag ordinarie utdelning CRNA 0.00 NOK
2020-04-29 - Årsstämma
2020-03-11 - Bokslutskommuniké 2019
2019-11-07 - Kvartalsrapport 2019-Q3
2019-08-22 - Kvartalsrapport 2019-Q2
2019-05-09 - Kvartalsrapport 2019-Q1
2019-04-10 - X-dag ordinarie utdelning CRNA 0.00 NOK
2019-04-09 - Årsstämma
2019-02-14 - Bokslutskommuniké 2018
2018-11-01 - Kvartalsrapport 2018-Q3
2018-08-23 - Kvartalsrapport 2018-Q2
2018-05-03 - Kvartalsrapport 2018-Q1
2018-04-12 - X-dag ordinarie utdelning CRNA 0.00 NOK
2018-04-11 - Årsstämma
2018-02-15 - Bokslutskommuniké 2017
2017-11-16 - Kvartalsrapport 2017-Q3
2017-08-24 - Kvartalsrapport 2017-Q2
2017-04-25 - Kvartalsrapport 2017-Q1
2017-04-05 - Årsstämma
2017-02-16 - Bokslutskommuniké 2016
2016-11-17 - Kvartalsrapport 2016-Q3
2016-08-25 - Kvartalsrapport 2016-Q2
2016-05-12 - Kvartalsrapport 2016-Q1
2016-04-14 - X-dag ordinarie utdelning CRNA 0.00 NOK
2016-04-13 - Årsstämma
2015-06-23 - X-dag ordinarie utdelning CRNA 0.00 NOK
2015-06-22 - Årsstämma

Beskrivning

LandNorge
ListaOslo Bors
SektorHälsovård
IndustriBioteknik
Circio Holding är ett läkemedelsbolag. Bolaget specialistkompetens återfinns inom riktad immunterapi som används vid behandling av cancerpatienter. Bolagets verksamhet består av forskning och utveckling och läkemedlen säljs under separata varumärken. Ett flertal partnerskap på marknaden har ingåtts för att stärka samarbetet inom utvecklingen av ny immunterapi. Bolaget grundades 2010 och har sitt huvudkontor i Lysaker.

Intresserad av bolagets nyckeltal?

Analysera bolaget i Börsdata!

Vem äger bolaget?

All ägardata du vill ha finns i Holdings!

2026-01-30 19:44:00

NOT FOR DISTRIBUTION OR RELEASE, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, THE UNITED KINGDOM, AUSTRALIA, CANADA, HONG KONG OR JAPAN, OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL. THIS ANNOUNCEMENT DOES NOT CONSTITUTE AN OFFER OF ANY OF THE SECURITIES DESCRIBED HEREIN.

Oslo, 30 January 2026: Reference is made to the stock exchange announcement published by Circio Holding ASA (the “Company”) earlier today, 30 January 2026, regarding the final results of the rights issue and the private placement.

The following primary insiders and close associates to primary insiders have been allocated new shares and warrants in the Rights Issue and Private Placement, including new shares and warrants as commission for their pre-subscriptions in the Rights Issue:

  • Erik Digman Wiklund, the CEO of the Company, has been allocated 150,000 new shares and the corresponding number of warrants in the Rights Issue and private placement. In addition, Erik Digman Wiklund has been granted 44,000 new shares and the corresponding number of warrants as commission for his pre-subscription in the Rights Issue.
  • Digman AS, a company closely associated with Erik Digman Wiklund, the CEO of the Company, has been allocated 250,000 new shares and the corresponding number of warrants in the Rights Issue and private placement.
  • Ola Melin, Chief Operating Officer of the Company, has been allocated 150,000 new shares and the corresponding number of warrants in the Rights Issue and private placement. In addition, Ola Melin has been granted 16,500 new shares and the corresponding number of warrants as commission for his pre-subscription in the Rights Issue.
  • Thomas Birkballe Hansen, Chief Technology Officer of the Company, has been allocated 200,000 new shares and the corresponding number of warrants in the Rights Issue and private placement. In addition, Thomas Birkballe Hansen has been granted 22,000 new shares and the corresponding number of warrants as commission for his pre-subscription in the Rights Issue.
  • BioPharma Drug Licensing Group SL (“BioPharma”), a company closely associated with Lubor Gaal, the CFO of the Company, has been allocated 270,000 new shares and the corresponding number of warrants in the Rights Issue and private placement. In addition, Biopharma has been granted 29,700 new shares and the corresponding number of warrants as commission for pre-subscription in the Rights Issue.
  • Victor Levitsky, Chief Scientific Officer of the Company, has been allocated 250,000 new shares and the corresponding number of warrants in the Rights Issue and private placement. In addition, Victor Levitsky has been granted 27,500 new shares and the corresponding number of warrants as commission for his pre-subscription in the Rights Issue.
  • Sølen AS, a close associate of Thomas Falck, board member of the board of directors of the Company, has been allocated 200,000 new shares, and the corresponding number of warrants in the Rights Issue and private placement. In addition, Sølen AS has been granted 22,000 new shares and the corresponding number of warrants as commission for pre-subscription in the Rights Issue.
  • Diane Mary Mellett, board member of the board of directors of the Company, has been allocated 60,000 new shares and the corresponding number of warrants in the Rights Issue and private placement. In addition, Diane Mary Mellet has been granted 6,600 new shares and the corresponding number of warrants as commission for her pre-subscription in the Rights Issue.
  • Robert Forbes Burns, deputy member of the board of directors of the Company, has been allocated 11,542 new shares and the corresponding number of warrants in the Rights Issue and private placement.
  • Damian Marron, the Chairman of the board of directors of the Company, has been allocated 120,000 new shares and the corresponding number of warrants in the Rights Issue and private placement. In addition, Damian Marron has been granted 13,200 new shares and the corresponding number of warrants as commission for his pre-subscription in the Rights Issue.

Please see the attached notifications of trade for information regarding the subscription rights exercised by primary insiders in the Rights Issue and Private Placement.